Abstract:BACKGROUND:In this study the expression of COX-2 both in lung cancer tissues and tissues of benign disease of the lung is compared to explore the effect of COX-2 on occurrence and development of non-small cell lung cancer (NSCLC), and the relationship between COX-2 expression and clinical characteristics of patients with NSCLC. METHODS:The COX-2 expression, vascular endothelial growth factor (VEGF) expression and microvessel density (MVD) were detected in 78 NSCLC lung cancer tissues and 14 benign tissues of the lung by immunohistochemical method. RESULTS:Expression of COX-2 protein was significantly higher in cancer tissues (69.2%, 54/78) than paired noncancerous tissues (14.3%, 2/14)(Chi-square=15.044, P < 0.01). There was significant difference of MVD between COX-2 positive lung cancers (19.41±8.56) and negative ones(12.00±5.37)(t=3.906, P < 0.01). There was no significant relationship between COX-2 protein expression and patients' age, sex, TNM stages and smoking status (P > 0.05); for different pathological types, COX-2 protein expression was remarkably higher in adenocarcinoma (88.9%, 32/36) than that in squamous cell carcinoma (50.0%, 20/40) (Chi-square=13.262, P < 0.01); and for squamous cell carcimoma it was significantly higher in low differentiated ones (81.0%, 17/21) than that in high differentiated ones (15.8%, 3/19) (Chi-square=16.942,P < 0.01); for adenocarcinoma it was also remarkably higher in low differentiated ones (100.0%, 18/18) than that in high differentiated ones ( 77.8% , 14/18) (Chi-square=6.046, P < 0.05).The expressions of COX-2 and VEGF in NSCLC were significantly positively correlated (r=0.509, P < 0.01), so were the expressions of VEGF and MVD (r=0.324, P < 0.01), and the expressions of COX-2 and MVD (r=0.477, P < 0.01). Controlling for VEGF, there still was significant correlation between COX-2 and MVD (r=0.383, P < 0.01). CONCLUSIONS:The present study suggests that there is overexpression of COX-2 in lung cancer, which is closely related to angiogenesis of lung cancer. Further studies, therefore, are needed to find the exact mechanisms.

Expression,Clinical Significance and Relativity of Gene PTEN and COX-2 in Breast Carcinoma

The Clinical Significance of PTEN Protein Expression in Colorectal Carcinoma

[Study of COX-2 Expression and Angiogenesis in Non-Small Cell Lung Cancer].

Expression and significance of hTERT and COX-2 in breast cancer

Expressions of COX-2 and MMP-2 in Breast Cancer and Their Significances

The Expression of COX-2 and VEGF in Breast Cancer and Their Clinical Significance to Prognsis

Expression and Significance of Tumor Suppressor Gene PTEN and Cyclooxygenase-2 in Colorectal Cancer

Expressions of COX-2,E-cad Gene and Protein in Invasive Ductal Carcinoma and the Clinical Significance

Expression and Clinical Significance of COX-2, Survivin in Breast Benign Lesion and Breast Carcinoma

Expression of COX-2 and HER-2 in human breast cancer and their relationship

Expression of COX-2 and Its Significance in Breast Cancer

Relationship between cyclooxygenase-2,p53 and microvascular density and lymph node metastasis in breast carcinoma

Clinical Value of the Expression of PTEN Gene,Progesterone Receptor and Estrogen Receptor for Predicting Biological Behaviors and Prognosis of Breast Carcinoma

Expression of PTEN Protein and the Clinical Value of the Expression in Primary Breast Carcinoma

Expression of PTEN and Its Significance in Breast Cancer

The Expression and Clinical Significance of COX-2 and HER-2 in Non-small Cell Lung Cancer

Expression of cyclooxygenase-2 in pancreaticcancer and its correlation with p53

Correlation of Expression of COX-2 to Clinical Pathological Characters and Its Catalytic Products in Gastric Carcinoma

The Association of Expressions of PTEN Gene and Nm23 Gene with Biological Behaviors in Breast Cancer

Expression of PTEN and CD147 and AKT2 in Gastric Carcinoma Tissues and the Clinical Significance

Expression and Clinical Significance of Β-Catenin and COX-2 in Human Colorectal Carcinoma